Introduction
============

The nonmotor symptoms (NMS) of Parkinson's disease (PD) are recognized as important disability-causing factors. NMS include autonomic dysfunction,[@b1-ndt-11-2865] neuropsychological problems,[@b2-ndt-11-2865] sleep disturbance,[@b3-ndt-11-2865],[@b4-ndt-11-2865] and sensory symptoms.[@b5-ndt-11-2865] These symptoms constitute a burden on the caregiver and the public health system. In the PRIAMO study,[@b6-ndt-11-2865] up to 98.6% of PD patients had NMS. Recently, the correlation between NMS and PD patients' health-related quality of life (HRQoL) has been emphasized. Several studies indicate that NMS, rather than motor symptoms, are a major cause of poor HRQoL.[@b7-ndt-11-2865]--[@b9-ndt-11-2865] The NMS screening questionnaire (NMSQuest), a self-completed questionnaire comprising 30 items, is a rapid screening tool for the early detection of patients' NMS.[@b10-ndt-11-2865],[@b11-ndt-11-2865] Previous studies have compared NMS in different countries and showed more prevalent gastrointestinal symptoms in Asian countries, probably due to ethnic and economic differences.[@b12-ndt-11-2865],[@b13-ndt-11-2865] However, the NMSQuest is still not routinely used for Taiwanese PD patients. Demographic data regarding NMS in Taiwanese PD patients remain unknown.

The pathophysiology of NMS is suspected to involve dopamine, noradrenaline, and serotonin. A previous review indicated that current dopaminergic anti-Parkinson medication has a limited effect on NMS.[@b14-ndt-11-2865] Although dopamine agonists reportedly have some antidepression effects,[@b15-ndt-11-2865],[@b16-ndt-11-2865] they also precipitate other NMS, such as orthostatic hypotension, hallucination, and impulse control diorder.[@b17-ndt-11-2865]--[@b19-ndt-11-2865] Thus, whether dopamine agonists improve patients' NMS and HRQoL remains a point of controversy.

The purpose of our study is to investigate the prevalence of NMS in PD patients in Taiwan and the impact of NMS on HRQoL since few studies on NMS have been conducted in Asian PD patients and the effects of anti-PD drugs, especially dopamine agonists, on risk of NMS are still controversial. We therefore conducted this hospital-based cross-sectional study to examine the clinical factors, including concomitant anti-PD medication use, on the occurrence of NMS and HRQoL in Taiwanese PD patients. We used the NMSQuest and 39-item Parkinson's Disease Questionnaire (PDQ-39) to explore the correlation among NMS, clinical factors, pharmacological therapy, and HRQoL.

Materials and methods
=====================

Patients
--------

This cohort study was conducted in the neurology department of National Taiwan University Hospital (NTUH), a tertiary referred medical center in Taipei, Taiwan. From February 2014 to December 2014, PD patients who fulfilled the United Kingdom Parkinson's Disease Brain Bank Criteria[@b20-ndt-11-2865] and received long-term follow-up in NTUH movement disorder clinics were recruited. Patients who were diagnosed with atypical parkinsonism or secondary parkinsonism were excluded. Since the National health insurance of Taiwan pays the cost of the anti-cholinesterase inhibitor, rivastigmine, for subjects with PD with dementia, we therefore excluded subjects with concomitant use of rivastigmine to exclude participants with PD with dementia.[@b21-ndt-11-2865] All patients in this study provided written informed consent. The study was approved by the Ethical Research Committee of NTUH.

Measures
--------

Patients who fulfilled the diagnostic criteria were asked to complete the Chinese version of the NMSQuest[@b22-ndt-11-2865] and PDQ-39[@b23-ndt-11-2865] while they were in the waiting room of the clinic. Previous studies have validated the Chinese versions of these two tests and the reliability of each domain of these two tests in the Chinese version are between 71% and 95%, which represents an acceptable psychometric property. If necessary, aid from patients' caregivers or a nurse was acceptable. Demographic data, including patients' age, sex, age at onset, duration, Hoehn and Yahr (H&Y) stage, disease type, and current medication, were collected from medical records. Patients' disease type was classified as tremor-at-onset type or bradykinesia/rigidity-at-onset type by review of their medical record, depending on their initial presentation at their first visit to our clinics.[@b24-ndt-11-2865],[@b25-ndt-11-2865] Individuals with resting tremor predominant as initial presentation were classified as tremor-at-onset type; others were classified as bradykinesia/rigidity-at-onset type.

The NMSQuest is a validated self-completed yes--no-type questionnaire to assess patients' NMS. This 30-items questionnaire measure nine domains of NMS: digestive, urinary, sexual, cardiovascular, memory/apathy, hallucination/delusion, depression/anxiety, sleep, and miscellany.[@b10-ndt-11-2865] Positive responses are summed up to yield a total score (NMSQT) that ranges from 0 to 30. Higher scores indicate worse NMS condition.[@b11-ndt-11-2865] The prevalence of each item was calculated on the total 210 samples by computing the number of positive responses and transforming them into a percentage. Positive answers in each domain were summed to obtain the score for the domain. The standardized prevalence of each domain was calculated by the number of positive responses divided by the total number of responses in the domain and transforming this values into a percentage.

Patients' HRQoL was assessed by the PDQ-39,[@b7-ndt-11-2865] which contains 39 items. Each item was rated by the patients using one of five categories, from 0 (never) to 4 (very frequent). PDQ-39 summary index (PDQSI) was calculated by dividing the sum of the total raw score by the maximum possible score (156 or 152 points, depending on the patient's marriage status) and multiplying by 100. In this study, we used PDQSI as a standardized index for representing PD patients' life quality.

Statistical analysis
--------------------

Spearman's rank correlation coefficient was calculated to check the correlation between clinical factors, pharmacological therapy, NMSQT, and PDQSI. *P*-values of less than 0.05 were accepted as significant. The strength of the association for correlation coefficients was interpreted as follows: ≤0.19, negligible correlation; 0.20--0.39, weak correlation; 0.40--0.59, moderate correlation; 0.60--0.79, strong correlation; and ≥0.80, very strong correlation.[@b26-ndt-11-2865] A stepwise multiple linear regression analysis was calculated to demonstrate which clinical factors contributed significantly to NMSQT. Age, sex, age at PD onset, duration of PD symptoms, H&Y stage, levodopa dosage, and dopamine agonist dosage (transformed into levodopa-equivalent dosage)[@b27-ndt-11-2865] were involved as independent variables. Owing to collinearity between patients' current age and their age at disease onset (*r*=0.92), age at PD onset was transformed into dummy variables (\<50 years =0; ≥50 years =1). Stepwise multiple linear regression analysis was also applied to assess the contribution of clinical factors to the PDQSI. For the regression model of PDQSI, we involved the aforementioned factors and NMSQT as independent variables.

To compare our prevalence of each symptom with others', we chose two international studies (one included only Europe and USA, the other included Europe, USA, Israel, and Japan) and one study from People's Republic of China. *χ*^2^ test was used for comparison ([Table S1](#SD1-ndt-11-2865){ref-type="supplementary-material"}).[@b10-ndt-11-2865],[@b28-ndt-11-2865],[@b29-ndt-11-2865] SPSS version 22.0 was used for the statistical analyses.

Results
=======

We collected data from 210 patients (110 males, 100 females; mean age: 66.1±9.86 years; median: 67 years; mode: 63 years; age range: 33--86 years; mean age at onset: 60±10.53 years; median: 61 years; mode: 61 years; onset age range: 26--83; disease duration 6.11±4.13 years; and H&Y stage 2.2±0.9). Demographic data are shown in [Table 1](#t1-ndt-11-2865){ref-type="table"}. Half of our subjects were in H&Y stage 2. Most of our patients were using levodopa (97.6%) and dopamine agonists (81%).

The result of NMSQuest and PDQ-39 are shown in [Table 2](#t2-ndt-11-2865){ref-type="table"}. The mean NMSQT was 7.77±4.74, which was considered as moderate in severity according to a previous study.[@b11-ndt-11-2865] The prevalence of NMS was 98.57%. Only three patients had no NMS. Among 30 NMS, nocturia was the most frequently reported NMS (prevalence =62.86%). Constipation was the second most prevalent problem among patients (prevalence =50.95%). The least frequent complaint was bowel incontinence, which happened in 2.86% of patients ([Table S1](#SD1-ndt-11-2865){ref-type="supplementary-material"}). Of the nine NMS subdomains, the urinary domain had the highest prevalence (56.19%), followed by memory/apathy (30.48%) and depression/anxiety (27.86%), while hallucination/delusion had the lowest prevalence (9.76%). The mean PDQSI was 16.13±15.61.

Spearman's rank correlation coefficients indicated that the NMSQT and all subdomains correlated with the PDQSI ([Table 3](#t3-ndt-11-2865){ref-type="table"}). NMSQT had stronger correlation with PDQSI than H&Y stage (*r*~s~ of NMSQT =0.667; *r*~s~ of H&Y stage =0.503). Among nine NMS subdomains, depression/anxiety correlated most strongly with PDQSI (*r*~s~=0.607), while the urinary domain exhibited the weakest correlation (*r*~s~=0.172). Age and disease types at onset did not significantly correlate with NMSQT and PDQSI, but there was significant difference between sexes in some NMS subdomains ([Table S2](#SD2-ndt-11-2865){ref-type="supplementary-material"}). Females had higher scores in memory/apathy and depression/anxiety (prevalence of memory/apathy, female vs male: 57% vs 47%, average score: 1.1 vs 0.75; prevalence of depression/anxiety, female vs male: 42% vs 29%, average score: 0.69 vs 0.44). Males had higher a score in sexual symptoms (prevalence of sexual dysfunction, female vs male: 26% vs 41%, average score: 0.34 vs 0.6). The PDQSI, NMSQT, and almost all NMS subdomains were correlated positively with disease duration, H&Y stage, and levodopa dosage. However, dopamine agonist dosage did not correlate significantly with the PDQSI, NMSQT, or almost all subdomains.

The regression model for the NMSQT indicated that duration of disease and H&Y stage were independent variables ([Table 4](#t4-ndt-11-2865){ref-type="table"}). The regression model for the PDQSI revealed that independent variables included NMSQT, H&Y stage, age at onset, and sex ([Table 4](#t4-ndt-11-2865){ref-type="table"}).

Discussion
==========

This was the first study, to our knowledge, to use NMSQuest to evaluate NMS in Taiwanese PD patients. In our study of 210 PD patients, we observed a high prevalence rate of NMS (98.57%). Among nine subdomains, the most prevalent domains were urinary complaints, followed by memory/apathy and depression/anxiety. NMSQT and all subdomains were correlated with the PDQSI. Among those subdomains, depression/anxiety had the strongest correlation coefficient with the HRQoL of PD patients. The regression model indicated that disease duration and severity were major predictors of NMS. Concomitant use of anti-PD medication, including dopamine agonist, was not correlated with the occurrence of NMS or HRQoL of patients with PD.

The general prevalence of NMS in our study was close to that of previous studies in other countries ([Table S3](#SD3-ndt-11-2865){ref-type="supplementary-material"}).[@b10-ndt-11-2865],[@b13-ndt-11-2865],[@b28-ndt-11-2865]--[@b38-ndt-11-2865] This indicates that NMS are very frequent and universal concerns in PD patients.[@b6-ndt-11-2865] For each item in NMSQuest, we compared our study with the studies of Chaudhuri et al,[@b10-ndt-11-2865] Martinez-Martin et al,[@b28-ndt-11-2865] and Gan et al.[@b29-ndt-11-2865] The results showed that there were no significant differences in most NMS rates between studies ([Table S1](#SD1-ndt-11-2865){ref-type="supplementary-material"}). The three most common symptoms in our study were nocturia (62.85%), constipation (50.95%), and urgency (49.52%), and the least common symptom was bowel incontinence (2.86%). This result was the same as Chaudhuri[@b10-ndt-11-2865] and Martinez-Martin's studies[@b28-ndt-11-2865] in Europe and USA. In contrast, studies in the People's Republic of China[@b29-ndt-11-2865]--[@b32-ndt-11-2865] revealed that the most common symptom was easily forgetting (prevalence: 56.1%--68.56%) ([Table S3](#SD3-ndt-11-2865){ref-type="supplementary-material"}). This suggests that factors other than race, such as age, disease duration, treatment strategy, education, and economical status, may be more influential on NMS. Further study for comparison among groups is needed. Previous studies have suggested that Asian PD patients may have higher rates of constipation or gastrointestinal problems.[@b12-ndt-11-2865],[@b13-ndt-11-2865] However, our study and one recent large-scale study from the People's Republic of China[@b30-ndt-11-2865] showed that constipation rates were not higher than Western groups ([Table S3](#SD3-ndt-11-2865){ref-type="supplementary-material"}). Ethnic effect on NMS is still controversial.

Although urinary symptoms were the most common in patients, the correlation between urinary symptoms and HRQoL was lowest (*r*~s~=0.176). This may be due to the fact that urinary symptoms rarely induce motor disturbance and psychosocial problems, which are mainly evaluated in PDQ-39. Measurement bias should be carefully considered when evaluating the impact of urinary symptoms on patients' life quality. Neuropsychological symptoms exerted the greatest influence over our patients' quality of life; among those, depression/apathy correlated most strongly with PDQSI (*r*~s~=0.607). This finding is consistent with previous studies indicating that depression has the greatest impact on PD patients.[@b8-ndt-11-2865],[@b12-ndt-11-2865],[@b26-ndt-11-2865],[@b28-ndt-11-2865],[@b39-ndt-11-2865] In our study, 30% of patients self-reported having depressed mood, which was compatible with the newest meta-analysis on the prevalence of depression among individuals with a PD diagnosis (36.6%).[@b40-ndt-11-2865] Depression is two- to threefold more prevalent among PD patients compared to healthy people, and can precede the diagnosis of PD by 4--6 years.[@b41-ndt-11-2865] This evidence suggests an underlying neurodegenerative process for depression in PD patients. Braak et al's pathology study demonstrated that the degeneration of PD is not limited to the substantia nigra; it also affects the locus coeruleus and raphe nucleus before the beginning of PD motor symptoms.[@b42-ndt-11-2865] This finding indicates that noradrenaline and serotonin were also involved in the pathology of depression in PD. Positron emission tomography has provided evidence of decreasing dopamine and noradrenaline transporter levels in the locus coeruleus and several regions of limbic system.[@b43-ndt-11-2865] ^18^F-fluorodeoxyglucose positron emission tomography has shown decreasing availability of the serotonergic 1A receptor in the limbic and orbitofrontal regions.[@b44-ndt-11-2865] Several studies that employed resting-state functional magnetic resonance imaging have revealed reduced functional connectivity in the prefrontal--limbic network in PD patients with depression.[@b45-ndt-11-2865]--[@b47-ndt-11-2865]

Pramipexole was found to improve depression in 12 weeks in 323 depressive PD patients.[@b15-ndt-11-2865] In that study, the Beck Depression Inventory score decreased by 5.9 points in the pramipexole group, compared with 4.0 points in the placebo group. In another study that involved only 44 patients, the Hamilton Anxiety Scale and the Montgomery--Asberg Depression Rating Scale also dropped in PD patients using ropinirole.[@b48-ndt-11-2865] However, in the present study, we did not find a significant correlation between calculated dopamine agonist dosage and NMSQT (including all subdomains) ([Table S2](#SD2-ndt-11-2865){ref-type="supplementary-material"}). In addition, we compared NMSQT, score of depression/anxiety subdomain, and PDQSI between the patients with and without using dopamine agonists. None of those showed significant difference (Mann--Whitney test; NMSQT: *P*=0.766; depression/anxiety: *P*=0.111; PDQSI: *P*=0.406). The negative results indicate that dopamine agonists did not eliminate depression and might not improve patients' life quality. However, only a yes/no question can be answered for each symptom in NMSQuest. Dopamine agonists cannot completely eliminate depressive symptoms but they may partially relieve the depression symptoms. The Non-Motor Symptoms Scale,[@b49-ndt-11-2865] another assessment tool which is able to evaluate the severity of each symptom, should be applied for further evaluation of dopamine agonists' antidepression effects.

Our regression model demonstrates that only disease severity and duration are independent variables for NMSQT. In contrast to Martinez-Martin et al's study,[@b28-ndt-11-2865] our regression model does not reveal age of onset as an independent predictor. In our correlation study, patients with young-onset PD (YOPD) surprisingly had higher NMSQT and PDQSI (ie, worse HRQoL), possibly because our YOPD group featured longer disease duration (YOPD vs late-onset PD \[LOPD\]: 7.9 years vs 5.8 years). The other regression model for PDQSI indicates that NMSQT, H&Y stage, age at onset, and sex are independent values, in which NMSQ plays the most important role. This result is quite similar to previous studies' findings that NMS are the major predictor for patients' quality of life, suggesting that NMS cause more disability than motor symptoms.[@b7-ndt-11-2865]--[@b9-ndt-11-2865] In our regression model for PDQSI, sex and age at onset were also independent values, although they have minor roles. Looking at our data ([Figure 1](#f1-ndt-11-2865){ref-type="fig"}), YOPD and female patients had similar NMSQT (YOPD vs LOPD: 9.41 vs 7.48, *P*=0.238; female vs male: 7.95 vs 7.61, *P*=0.784). However, they had slightly higher PDQSI (YOPD vs LOPD: 22.3 vs 15.02, *P*=0.008; female vs male: 18.77 vs 13.74, *P*=0.202). This may indicate that, although they had similar number of NMS, they still subjectively felt that they had a poor life quality. In Dubayova et al's study,[@b50-ndt-11-2865] females also had slightly higher PDQ-39 scores although there was no significant difference. In female patients, age and neuroticism were more significantly correlated with PDQ-39 score than they were in males. In Nutt et al's study,[@b51-ndt-11-2865] multiple linear regression showed age and sex were independent variables contributing to PDQSI.

There are several limitations in the current study. Although our sample number is relatively small, it is comparable to other studies ([Table S3](#SD3-ndt-11-2865){ref-type="supplementary-material"}). In addition, another limitation of our study is that few YOPD patients were involved (n=32), which may partly explain why age at onset did not play an important role in our study. Although YOPD predicts higher NMSQT in Martinez-Martin et al's study,[@b28-ndt-11-2865] another study indicated that patients with LOPD have more gastrointestinal and urinary symptoms, dementia, and psychosis, which influence patients' quality of life more.[@b52-ndt-11-2865] To better understand the differences in NMS between YOPD and LOPD patients, more YOPD patients should be included in future studies.

Conclusion
==========

Our findings indicate that NMS are common in PD patients and determine the life quality of PD patients. NMS severity is positively correlated with disease severity and duration. Among NMS subdomains, depression and other neuropsychological symptoms most influence patients' quality of life. However, concomitant anti-PD medication use did not affect the occurrence of NMS and quality of life. Further study for treatment of NMS is mandatory to improve the life quality of patients.

Supplementary materials
=======================

###### 

Comparison of the prevalence of each nonmotor symptom with other studies

                              Current study (%)   Martinez- Martin et al[@b53-ndt-11-2865] (%)   *P*-value (*χ*^2^ test)                               Chaudhuri et al[@b54-ndt-11-2865] (%)   *P*-value (*χ*^2^ test)                             Gan et al[@b55-ndt-11-2865] (%)   *P*-value (*χ*^2^ test)
  --------------------------- ------------------- ---------------------------------------------- ----------------------------------------------------- --------------------------------------- --------------------------------------------------- --------------------------------- -----------------------------------------------------
  Dribbling                   27.14               41.52                                          0.026[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}     35                                      0.14                                                17.70                             0.128
  Taste/smelling              16.19               28.95                                          0.028[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}     26                                      0.054                                               22.20                             0.279
  Swallowing                  29.52               28.38                                          0.755                                                 23.6                                    0.433                                               23.40                             0.28
  Vomiting                    12.38               14.31                                          0.674                                                 8.1                                     0.397                                               8.20                              0.358
  Constipation                50.95               52.48                                          0.887                                                 46.7                                    0.831                                               64.60                             0.036[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}
  Bowel incontinence          2.86                8.21                                           0.121                                                 4.9                                     0.435                                               0.60                              0.312
  Bowel emptying incomplete   35.71               29.90                                          0.367                                                 27.6                                    0.308                                               15.20                             0.001[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}
  Urgency                     49.52               55.81                                          0.395                                                 61                                      0.022[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}   31.00                             0.006[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}
  Nocturia                    62.86               61.90                                          0.884                                                 66.7                                    0.116                                               61.40                             0.84
  Pains                       22.86               28.76                                          0.333                                                 27.6                                    0.225                                               27.20                             0.487
  Weight                      16.67               18.29                                          0.852                                                 22                                      0.25                                                22.20                             0.353
  Memory                      38.10               44.85                                          0.315                                                 43.9                                    0.169                                               65.80                             \<0.001[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}
  Loss of interest            26.19               34.67                                          0.167                                                 29.3                                    0.425                                               48.70                             \<0.001[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}
  Hallucinations              13.33               22.52                                          0.066                                                 19.5                                    0.143                                               11.40                             0.663
  Concentrating               27.14               45.71                                          0.005[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}     37.4                                    0.03[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}    38.00                             0.097
  Sadness/blues               30.00               50.10                                          0.004[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}     44.7                                    0.018[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}   36.70                             0.228
  Anxiety                     25.71               45.33                                          0.005[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}     39.9                                    0.011[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}   30.40                             0.471
  Sex drive                   24.29               34.17                                          0.119                                                 29.3                                    0.073                                               16.50                             0.296
  Sex difficulty              23.33               32.43                                          0.154                                                 24.4                                    0.166                                               12.00                             0.064
  Dizzy                       34.76               37.14                                          0.768                                                 39.8                                    0.308                                               16.50                             0.004[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}
  Falling                     13.81               28.00                                          0.015[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}     30.9                                    0.002[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}   25.90                             0.031[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}
  Daytime sleepiness          12.86               31.11                                          0.002[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}     28.4                                    0.005[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}   38.60                             \<0.001[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}
  Insomnia                    37.14               45.71                                          0.196                                                 40.6                                    0.414                                               39.20                             0.728
  Vivid dreams                39.52               33.90                                          0.38                                                  30.9                                    0.31                                                43.70                             0.486
  RBD                         35.24               35.69                                          0.883                                                 32.5                                    0.927                                               27.80                             0.332
  Restless legs               25.24               41.71                                          0.011[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}     37.4                                    0.024[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}   20.30                             0.419
  Swelling                    14.29               31.30                                          0.004[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}     30.9                                    0.001[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}   8.20                              0.183
  Sweating                    10.48               29.90                                          \<0.001[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}   25.2                                    0.002[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}   28.50                             0.001[\*](#tfn5-ndt-11-2865){ref-type="table-fn"}
  Diplopia                    12.86               20.00                                          0.182                                                 21.9                                    0.065                                               5.70                              0.096
  Delusions                   6.19                11.07                                          0.205                                                 12.3                                    0.11                                                12.00                             0.132

**Notes:**

Indicates statistical significance. Adapted with permission from Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. *Movement Disorders*. 2007;22(11):1623--1629. Published by John Wiley and Sons. Copyright © 2007 Movement Disorder Society.[@b53-ndt-11-2865] And adapted with permission from Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. *Movement Disorders*. 2006;21(7):916--923. Published by John Wiley and Sons. Copyright © 2006 Movement Disorder Society.[@b54-ndt-11-2865] And adapted from *Journal of Clinical Neuroscience*. 2014;21(5). Gan J, Zhou M, Chen W, Liu Z. Non-motor symptoms in Chinese Parkinson's disease patients. 751--754. With permission from Elsevier. Copyright © 2013 Elsevier Ltd. All rights reserved.[@b55-ndt-11-2865]

**Abbreviation:** RBD, rapid eye movement sleep behavior disorder.

###### 

Correlations of clinical factors with NMSQT, subdomains, and PDQSI

                 NMSQT                                                 Digestive                                             U                                                   M/A                                                 H/D                                                   Dep/An                                                Sexual[\#](#tfn9-ndt-11-2865){ref-type="table-fn"}   CV                                                    Sleep                                               Mis                                                 Auto                                                NP                                                    PDQSI
  -------------- ----------------------------------------------------- ----------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------
  Sex (*r*~s~)   −0.019                                                0.054                                                 0.072                                               −0.144                                              −0.033                                                −0.15                                                 0.172                                                −0.071                                                0.057                                               −0.106                                              0.078                                               −0.155                                                −0.088
  (*P*-value)    0.785                                                 0.428                                                 0.301                                               0.037[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.633                                                 0.03[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}      0.013[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}    0.303                                                 0.411                                               0.126                                               0.263                                               0.025[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}     0.202
  Age            −0.041                                                0.026                                                 0.122                                               −0.05                                               0.084                                                 0.006                                                 −0.099                                               −0.071                                                −0.082                                              −0.042                                              −0.007                                              0.016                                                 0.039
                 0.552                                                 0.712                                                 0.078                                               0.493                                               0.224                                                 0.926                                                 0.151                                                0.308                                                 0.237                                               0.544                                               0.918                                               0.887                                                 0.077
  Disease type   −0.012                                                0.033                                                 0.008                                               −0.085                                              −0.125                                                −0.017                                                0.056                                                0.013                                                 0.028                                               −0.004                                              0.002                                               −0.095                                                0.108
  at onset       0.858                                                 0.631                                                 0.903                                               0.221                                               0.07                                                  0.805                                                 0.418                                                0.848                                                 0.69                                                0.957                                               0.975                                               0.17                                                  0.12
  Age at onset   −0.163                                                −0.075                                                0.096                                               −0.121                                              0.012                                                 −0.116                                                −0.132                                               −0.174                                                −0.137                                              −0.13                                               −0.085                                              −0.099                                                −0.111
                 0.018[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}     0.278                                                 0.165                                               0.081                                               0.866                                                 0.093                                                 0.056                                                0.012[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}     0.047[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.06                                                0.222                                               0.152                                                 0.108
  Duration       0.322                                                 0.251                                                 0.053                                               0.241                                               0.202                                                 0.257                                                 0.164                                                0.288                                                 0.144                                               0.2                                                 0.225                                               0.288                                                 0.353
                 \<0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   \<0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.449                                               0.002[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.003[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}     \<0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.017[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}    \<0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.038[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.004[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   \<0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   \<0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}
  H&Y stage      0.324                                                 0.265                                                 0.191                                               0.17                                                0.258                                                 0.253                                                 0.071                                                0.207                                                 0.143                                               0.2                                                 0.186                                               0.295                                                 0.503
                 \<0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   \<0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.005[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.013[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   \<0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   \<0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.305                                                0.003                                                 0.039[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.004[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.007[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   \<0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   \<0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}
  LD             0.296                                                 0.217                                                 0.125                                               0.146                                               0.221                                                 0.173                                                 0.086                                                0.204                                                 0.193                                               0.167                                               0.17                                                0.236                                                 0.408
                 \<0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.002[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}     0.070                                               0.034[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}     0.012[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}     0.212                                                0.003[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}     0.005[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.015[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.014[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}   0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}     \<0.001[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}
  DA dose        0.082                                                 0.099                                                 −0.027                                              −0.046                                              0.024                                                 --0.086                                               0.105                                                0.058                                                 0.085                                               0.15                                                0.038                                               −0.62                                                 0.078
                 0.234                                                 0.152                                                 0.702                                               0.507                                               0.726                                                 0.215                                                 0.128                                                0.404                                                 0.22                                                0.03[\*](#tfn8-ndt-11-2865){ref-type="table-fn"}    0.581                                               0.371                                                 0.263

**Notes:** Auto contains urinary, sexual, and CV subdomains. NP contains M/A, H/D, and Dep/An subdomains.

Indicates significance.

Sexual dysfunction.

**Abbreviations:** Auto, autonomic dysfunction; CV, cardiovascular problems; DA dose, dopamine agonist equivalence dose; Dep/An, depression/anxiety; H&Y, Hoehn and Yahr stage; H/D, hallucination/delusion; LD, levodopa dose; M/A, memory/apathy; Mis, miscellany; NMSQT, nonmotor symptoms questionnaire total score; NP, neuropsychological problems; PDQSI, 39-item Parkinson's Disease Questionnaire summary index; *r*~s~, Spearman's rank correlation coefficient; U, urinary.

###### 

NMS prevalence and rate of constipation and memory symptoms in other studies

  Study                                     Location                               Subject number                                                           Age (mean ± standard deviation), years   Prevalence (%)   Constipation rate (%)   Memory rate (%)   Number of NMS per patient
  ----------------------------------------- -------------------------------------- ------------------------------------------------------------------------ ---------------------------------------- ---------------- ----------------------- ----------------- ---------------------------
  Current study                             Taiwan                                 210                                                                      66.1±9.86                                98.6             50.95                   38.1              7.77
  Martinez-Martin et al[@b53-ndt-11-2865]   International                          525 (Japan =10, USA =42, UK =209, Italy =132, Germany =81, Israel =51)   67.66±10.5                               98.4             52.48                   44.85             10.25
  Chaudhuri et al[@b54-ndt-11-2865]         International                          123 (UK, USA, Italy, and Germany)                                        68.1±10.3                                97.6             46.7                    43.9              9.48
  Gan et al[@b55-ndt-11-2865]               Shanghai, People's Republic of China   155                                                                      71.73±8.82                               98.7             64.56                   65.8              8.29
  Wu et al[@b56-ndt-11-2865]                Sichuan, People's Republic of China    301                                                                      58.4±10.9                                Not given        29.6                    58.1              8.0
  Zhang et al[@b57-ndt-11-2865]             Nanjing, People's Republic of China    493                                                                      65.06±10.76                              98.88            57.2                    68.56             10.45
  Li et al[@b58-ndt-11-2865]                Beijing, People's Republic of China    1,225                                                                    61.48±10.47                              97.6             55.3                    56.1              8.72
  Cheon et al[@b59-ndt-11-2865]             Korea                                  74                                                                       64.9±8.6                                 98.6             65.8                    60.8              5.2
  Tsuboi et al[@b60-ndt-11-2865]            Japan                                  53                                                                       66.1±11.2                                Not given        78.4                    64.7              Not given
  Rukmini Mridula et al[@b61-ndt-11-2865]   India                                  53                                                                       56.64±8.22                               100              71                      25                8.4
  Cosentino et al[@b62-ndt-11-2865]         Peru                                   300                                                                      64.01±10.25                              99.7             55.7                    60.7              12.41
  Khedr et al[@b63-ndt-11-2865]             Egypt                                  112                                                                      61±12.7                                  96.4             51.79                   30.36             9.52
  Bostantjopoulou et al[@b64-ndt-11-2865]   Greece                                 164                                                                      59.5±9.3                                 97               45.7                    31.1              6.76
  Crosiers et al[@b65-ndt-11-2865]          Belgian                                215                                                                      67.1±10.4                                Not given        38.6                    37.9              9.02

**Abbreviation:** NMS, nonmotor symptoms.
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###### 

Demographic, clinical, and medical characteristics for our subjects

                                                   Range
  ----------------------------------- ------------ --------
  Patients, n                         210          
  Male/female                         110/100      
  Mean age ± SD, years                66.1±9.86    33--86
  Mean age at onset ± SD, years       60±10.53     26--83
  Age ≥50/age \<50, n                 173/37       
  Mean disease duration ± SD, years   6.11±4.13    0--23
  **H&Y stage, n (%)**                             
  Stage 1                             47 (22.4)    
  Stage 2                             98 (46.7)    
  Stage 3                             44 (21.0)    
  Stage 4                             20 (9.5)     
  Stage 5                             1 (0.5)      
  **Disease type at onset, n (%)**                 
  Tremor                              102 (48.6)   
  Bradykinesia/rigidity               108 (51.4)   
  **Medication, n (%)**                            
  Levodopa                            205 (97.6)   
  Dopamine agonist                    170 (81)     
  BZD                                 75 (35.7)    
  MAOBI                               36 (17.1)    
  Antidepressant                      7 (3.3)      
  Antipsychotics                      10 (4.8)     
  Anticholinergics                    59 (28.1)    
  Amantadine                          97 (46.2)    

**Abbreviations:** BZD, benzodiazepines; H&Y, Hoehn and Yahr; MAOBI, monoamine oxidase B inhibitor; SD, standard deviation.

###### 

Descriptive statistics of the NMSQT and PDQ-39 rating scales in 210 Taiwanese patients with Parkinson's disease

                                   Prevalence, %   Mean score ± SD   Range
  -------------------------------- --------------- ----------------- --------
  **NMSQuest (number of items)**                                     
  NMSQuest total score (30)        98.57           7.77±4.74         0--24
  **NMSQT domains**                                                  
  Digestive (7)                    24.97           1.75±1.38         0--6
  Urinary (2)                      56.19           1.12±0.74         0--2
  Sexual dysfunction (2)           23.81           0.48±0.73         0--2
  Cardiovascular (2)               24.29           0.49±0.62         0--2
  Memory/apathy (3)                30.48           0.91±1.06         0--3
  Hallucination/delusion (2)       9.76            0.20±0.48         0--2
  Depression/anxiety (2)           27.86           0.56±0.81         0--2
  Sleep disorders (5)              30.00           1.50±1.34         0--5
  Miscellany (5)                   15.43           0.77±0.97         0--5
  **PDQ-39**                                                         
  PDQ-39 total scores                              25.11±24.30       0--125
  PDQ-39 summary index                             16.13±15.61       0--119

**Abbreviations:** NMSQT, nonmotor symptoms questionnaire total score; PDQ-39, 39-item Parkinson's Disease Questionnaire; SD, standard deviation; NMSQuest, nonmotor symptoms questionnaire.

###### 

Correlations of scores of NMSQuest, Hoehn and Yahr stage, and PDQSI

                            *r*~s~   *P*-value
  ------------------------- -------- -----------
  Hoehn and Yahr stage      0.503    \<0.001
  NMSQT                     0.667    \<0.001
   Digestive                0.336    \<0.001
   Urinary                  0.172    0.013
   Sexual dysfunction       0.253    0.006
   Cardiovascular           0.403    \<0.001
   Memory/apathy            0.411    \<0.001
   Hallucination/delusion   0.371    \<0.001
   Depression/anxiety       0.607    \<0.001
   Sleep disorders          0.461    \<0.001
   Miscellany               0.376    \<0.001

**Abbreviations:** NMSQT, nonmotor symptoms questionnaire total score; NMSQuest, nonmotor symptoms questionnaire; *r*~s~, Spearman's rank correlation coefficient; PDQSI, 39-item Parkinson's Disease Questionnaire summary index.

###### 

Multiple linear regression analysis for NMSQT and PDQSI

                                                          Standardized beta   Standard error   95% CI            *P*-value
  ------------------------------------------------------- ------------------- ---------------- ----------------- -----------
  Regression model of the NMSQT (Adjusted *R*^2^=0.574)                                                          
   H&Y                                                    0.241               0.390            0.49--2.03        0.001
   Duration (years)                                       0.208               0.086            0.07--0.41        0.006
  Regression model of the PDQSI (Adjusted *R*^2^=0.613)                                                          
   H&Y                                                    0.402               0.793            5.35--8.48        \<0.001
   NMSQT                                                  0.509               0.153            1.38--1.98        \<0.001
   Age at onset                                           −0.113              1.776            −8.13 to −1.126   0.01
   Sex                                                    −0.175              1.349            −8.11 to −2.78    \<0.001

**Abbreviations:** CI, confidence interval; H&Y, Hoehn and Yahr stage; NMSQT, nonmotor symptoms questionnaire total score; PDQSI, 39-item Parkinson's Disease Questionnaire summary index.
